The basis of Medigene’s differentiation is our end-to-end platform of multiple, combinable, exclusive and proprietary technologies. These technologies build in both the potential of enhancing our TCR-T drug products from a safety and / or efficacy perspective as well as through optimizing our development processes at multiple sequential stages of development, from target screening, through TCR generation and optimization and ultimately into clinical development.

Target
Screening

TCR
Generation

TCR-T Therapy Optimization

Manufacturing Scale-Up and Process Improvement

Clinical Development
Target
Screening
Manufacturing Scale-Up and Process Improvement
Clinical Development
= Developmental Optimization Technology
= Efficacy Enhancement Technology
= Safety Enhancement Technology